Invesco
AVIR icon

Invesco’s Atea Pharmaceuticals AVIR Stock Holding History

Invesco’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.24M Buy
267,125
+133,777
+100% +$665K ﹤0.01% 2817
2026
Q1 		$717K Buy
133,348
+45,442
+52% +$209K ﹤0.01% 3003
2025
Q4 		$314K Sell
87,906
-36,478
-29% -$116K ﹤0.01% 3371
2025
Q3 		$361K Sell
124,384
-25,818
-17% -$88.2K ﹤0.01% 3356
2025
Q2 		$541K Sell
150,202
-22,954
-13% -$68.5K ﹤0.01% 3127
2025
Q1 		$518K Sell
173,156
-23,546
-12% -$73.5K ﹤0.01% 3138
2024
Q4 		$659K Buy
196,702
+2,173
+1% +$7.22K ﹤0.01% 3115
2024
Q3 		$652K Sell
194,529
-508
-0.3% -$1.84K ﹤0.01% 3116
2024
Q2 		$646K Sell
195,037
-1,227
-0.6% -$4.58K ﹤0.01% 3165
2024
Q1 		$793K Sell
196,264
-25,301
-11% -$99K ﹤0.01% 3105
2023
Q4 		$676K Buy
221,565
+9,454
+4% +$28.6K ﹤0.01% 3070
2023
Q3 		$636K Buy
212,111
+1,581
+0.8% +$5.38K ﹤0.01% 3088
2023
Q2 		$787K Sell
210,530
-6,244
-3% -$23.4K ﹤0.01% 3004
2023
Q1 		$726K Buy
216,774
+68,845
+47% +$279K ﹤0.01% 3067
2022
Q4 		$712K Buy
147,929
+31,289
+27% +$158K ﹤0.01% 3103
2022
Q3 		$664K Sell
116,640
-4,492
-4% -$34.4K ﹤0.01% 3094
2022
Q2 		$860K Buy
121,132
+16,114
+15% +$110K ﹤0.01% 3051
2022
Q1 		$758K Buy
105,018
+71,725
+215% +$487K ﹤0.01% 3204
2021
Q4 		$297K Sell
33,293
-284,286
-90% -$4.43M ﹤0.01% 3617
2021
Q3 		$11.1M Buy
317,579
+295,781
+1,357% +$8.2M ﹤0.01% 1939
2021
Q2 		$468K Buy
21,798
+13,256
+155% +$398K ﹤0.01% 3447
2021
Q1 		$527K Buy
+8,542
New +$577K ﹤0.01% 3320

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Invesco's AVIR Position: Q2 2026 in Review

Invesco increased its Atea Pharmaceuticals (AVIR) stake by 100% in Q2 2026, buying an estimated $665K and bringing the position to 267,125 shares worth $1.24M. The position accounts for ﹤0.01% of the portfolio, ranked #2817.

Invesco first reported a position in AVIR in Q1 2021 and has held it in 22 quarters since. The position peaked at $11.1M in Q3 2021. 125 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • Invesco held 267,125 shares of Atea Pharmaceuticals worth $1.24M as of Q2 2026.
  • Invesco bought 133,777 Atea Pharmaceuticals shares in Q2 2026, an estimated $665K.
  • Atea Pharmaceuticals made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #2817 holding.
  • Invesco first reported a position in Atea Pharmaceuticals in Q1 2021 and has held it in 22 quarters since.
  • Invesco's Atea Pharmaceuticals position peaked at $11.1M in Q3 2021.
  • 125 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.